Yuan-Yuan Lei1, Suzanne C Ho2, Ashley Cheng3, Carol Kwok3, Ka Li Cheung1, Yi-Qian He1, Roselle Lee1, Winnie Yeo4,5. 1. Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, New Territories, Hong Kong, SAR, China. 2. Division of Epidemiology, The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, New Territories, Hong Kong, SAR, China. 3. Department of Clinical Oncology, Princess Margaret Hospital, Hong Kong SAR, China. 4. Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, New Territories, Hong Kong, SAR, China. winnieyeo@cuhk.edu.hk. 5. Hong Kong Cancer Institute, State Key Laboratory in Oncology in South China, Faculty of Medicine, The Chinese University of Hong Kong, New Territories, Hong Kong, SAR, China. winnieyeo@cuhk.edu.hk.
Abstract
PURPOSE: This study investigated the association between soy isoflavone intake and menopausal symptoms (MPS) among Chinese women with early stage breast cancer in a prospective cohort study. METHODS: In an on-going prospective cohort study that involved 1462 Chinese women with early stage breast cancer, MPS were assessed at 18, 36 and 60 months after cancer diagnosis using the validated menopausal rating scale (MRS) questionnaire. Daily soy food intake for the previous 12 months was assessed at the same time using a validated food frequency questionnaire. The associations between MPS and soy isoflavone intake were evaluated in multivariable logistic regression analyses. RESULTS: The prevalence of MPS was almost the same during the first 60 months after cancer diagnosis, which were 64.5%, 65.2%, and 63.9% at 18, 36, and 60 months, respectively. Patients with MPS tended to be younger than those without MPS. The intake of soy isoflavones was not associated with the total score of MRS at 18-month follow-up [highest vs lowest tertile, odds ratio (OR) = 1.00, 95% CI 0.75-1.34]. Similarly, no significant association was noted at 36-month (OR = 1.25, 95% CI 0.92-1.69) and 60-month (OR = 1.21, 95% CI 0.84-1.74) follow-up. With regards to specific domain within MRS, the risk of symptoms presenting in somatic domain was higher among breast cancer patients who were in the highest tertile of soy isoflavone intake at 36 months post-diagnosis (OR = 1.44, 95% CI 1.07-1.94, P-trend = 0.02), compared with the lowest tertile, where a stronger significant association was noted among patients who were younger than 60 years (OR = 1.52, 95% CI 1.05-2.20, P-trend = 0.03) and pre-menopausal (OR = 3.81, 95% CI 1.85-8.11, P-trend < 0.01). CONCLUSION: The present study provided further evidence that soy isoflavone consumption was not associated with MPS among Chinese breast cancer patients. In fact, patients with higher intake of soy isoflavone have increased risk of experiencing somatic symptoms.
PURPOSE: This study investigated the association between soy isoflavone intake and menopausal symptoms (MPS) among Chinese women with early stage breast cancer in a prospective cohort study. METHODS: In an on-going prospective cohort study that involved 1462 Chinese women with early stage breast cancer, MPS were assessed at 18, 36 and 60 months after cancer diagnosis using the validated menopausal rating scale (MRS) questionnaire. Daily soy food intake for the previous 12 months was assessed at the same time using a validated food frequency questionnaire. The associations between MPS and soy isoflavone intake were evaluated in multivariable logistic regression analyses. RESULTS: The prevalence of MPS was almost the same during the first 60 months after cancer diagnosis, which were 64.5%, 65.2%, and 63.9% at 18, 36, and 60 months, respectively. Patients with MPS tended to be younger than those without MPS. The intake of soy isoflavones was not associated with the total score of MRS at 18-month follow-up [highest vs lowest tertile, odds ratio (OR) = 1.00, 95% CI 0.75-1.34]. Similarly, no significant association was noted at 36-month (OR = 1.25, 95% CI 0.92-1.69) and 60-month (OR = 1.21, 95% CI 0.84-1.74) follow-up. With regards to specific domain within MRS, the risk of symptoms presenting in somatic domain was higher among breast cancerpatients who were in the highest tertile of soy isoflavone intake at 36 months post-diagnosis (OR = 1.44, 95% CI 1.07-1.94, P-trend = 0.02), compared with the lowest tertile, where a stronger significant association was noted among patients who were younger than 60 years (OR = 1.52, 95% CI 1.05-2.20, P-trend = 0.03) and pre-menopausal (OR = 3.81, 95% CI 1.85-8.11, P-trend < 0.01). CONCLUSION: The present study provided further evidence that soy isoflavone consumption was not associated with MPS among Chinese breast cancerpatients. In fact, patients with higher intake of soy isoflavone have increased risk of experiencing somatic symptoms.
Entities:
Keywords:
Breast cancer; Chinese women; Menopausal symptoms; Soy isoflavone intake
Authors: Paul A Cohen; Annabelle Brennan; Jennifer L Marino; Christobel M Saunders; Martha Hickey Journal: Maturitas Date: 2017-04-22 Impact factor: 4.342
Authors: Richard J Santen; Cynthia A Stuenkel; Susan R Davis; JoAnn V Pinkerton; Anne Gompel; Mary Ann Lumsden Journal: J Clin Endocrinol Metab Date: 2017-10-01 Impact factor: 5.958
Authors: Yuan-Yuan Lei; Suzanne C Ho; Thomas K H Lau; Carol Kwok; Ashley Cheng; Ka Li Cheung; Roselle Lee; Winnie Yeo Journal: Qual Life Res Date: 2021-01-14 Impact factor: 4.147
Authors: Yuan-Yuan Lei; Suzanne C Ho; Carol Kwok; Ashley Cheng; Ka Li Cheung; Roselle Lee; Frankie K F Mo; Winnie Yeo Journal: Qual Life Res Date: 2021-09-16 Impact factor: 3.440
Authors: Yuanyuan Lei; Suzanne C Ho; Carol Kwok; Ashley C Cheng; Ka Li Cheung; Roselle Lee; Winnie Yeo Journal: Cancer Manag Res Date: 2021-06-08 Impact factor: 3.989